Clinical Research Directory
Browse clinical research sites, groups, and studies.
Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
This is a research study aiming to better understand a type of kidney cancer called Renal Cell Carcinoma (RCC). Doctors have observed that inside some larger RCC tumors, there are multiple smaller nodules. This study wants to find out if these nodules are different from each other and how they might be related. To do this, researchers will study tumor tissue samples from 10 patients with RCC who are having surgery. From each tumor, several nodules will be analyzed using advanced laboratory techniques. These techniques will create very detailed maps of the genes and cells within each nodule. At the same time, tiny 3D tumor models (called microtumors) will be grown from these samples in the lab to test how they respond to different cancer drugs. The main goal is to combine these two types of information to see how the differences in genes and cells between nodules might explain why some tumors stop responding to treatment (become resistant). We hope this study will lead to a deeper understanding of how RCC grows and spreads, and help find new ways to diagnose and treat it in the future.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2026-01-25
Completion Date
2030-01-25
Last Updated
2026-01-20
Healthy Volunteers
No
Conditions
Interventions
Multi-region Tumor Sampling and Integrated Multi-omics Analysis and Microtumor PTC Drug Sensitivity Assay
This integrated intervention involves: 1) Multi-region sampling of intratumoral nodules from resected RCC tumors for multi-omics analysis (single-cell RNA-seq, whole-exome sequencing, spatial transcriptomics) to map molecular and cellular heterogeneity. 2) Parallel generation of patient-derived microtumor (PTC) models from the same nodules for ex vivo drug sensitivity testing against a panel of oncology agents (e.g., Axitinib, Pembrolizumab). The core purpose is to correlate molecular features from omics with functional drug response data to decipher mechanisms of intra-tumoral heterogeneity and resistance.